Please login to the form below

Not currently logged in
Email:
Password:

Kite Pharma appoints Zelboraf scientist as CMO

Keith Nolop joins US cancer biotech from Plexxikon

Kite Pharma Keith NolopDr Keith Nolop, one of the chief scientists behind the development of Roche's personalised skin cancer drug Zelboraf, has been appointed chief medical officer of cancer specialist Kite Pharma.

Dr Nolop joins the US-based biotech from Plexxikon, where he served as senior VP and chief medical officer since 2004.

During this time, he was clinical lead for the development of Zelboraf (vemurafenib), which was co-developed by Roche and is predicted to reach peak-year sales of $1bn to $1.5bn after approvals in the US and EU.

At Plexxikon, he also led the filing of eight investigational New Drug Applications in cancer.

Prior to joining Plexxikon, Dr Nolop was VP of clinical research at CoTherix, where he led the development and US approval for Ventavis (iloprost) to treat pulmonary arterial hypertension (PAH).

He also spent 11 years at Schering-Plough, serving as clinical lead for three drug approvals.

"Dr Nolop's vast experience in drug development from conception to approval will be instrumental to advancing Kite's eACT products through multi-center clinical trials and on to registration," said Dr Aya Jakobovits, president and CEO of Kite Pharma.

"We are very pleased to welcome him to the Kite management team."

4th June 2013

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
ROAD

ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics